$AMRZ

Amrize names Samuel Poletti as chief financial officer

Amrize (NYSE:AMRZ) appointed Samuel J. Poletti as CFO, replacing Baris Oran. Poletti previously led Amrize's spin-off from Holcim. The company also named Dillon Cumming as VP of Investor Relations. Amrize reported $11.8B revenue in 2025 and operates 1,000 sites with 19,000 employees.

Original reporting
Published Aug 24, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 6:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AMRZ
Neutral
medium confidence
Mentioned
$AMRZ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRZNeutralMed
01

Why it matters

The CFO appointment provides fresh leadership but does not constitute a material corporate event.

02

Market read

Executive change news with moderate relevance for traders monitoring Amrize.

03

What to watch

Potential integration challenges from the recent spin‑off and broader market volatility.

Relevance 7/10Novelty 7/10Timing: effective today

Background

Amrize (NYSE:AMRZ) recently spun off from Holcim and operates over 1,000 sites in the U.S. and Canada.

Company-level read

Ticker impact

$AMRZNeutralMedium confidence
Context

Amrize announced the appointment of Samuel J. Poletti as its new Chief Financial Officer effective today.

Expected impact

Potential modest upside if market views the appointment positively.

Evidence & confidence

New CFO with extensive M&A experience could improve execution, but impact is uncertain.

Market effects

May signal stronger financial leadership for the building materials sector.

Limited to North American investors focused on Amrize.

Low

Counterpoint

The appointment may not translate into operational improvements, keeping the stock flat.

Key entities

  • Samuel J. Poletti

    New Chief Financial Officer of Amrize

  • Jan Jenisch

    Chairman and CEO of Amrize

Related articles

Low

Amrize (SWX:AMRZ) Reshuffles Building Envelope Leadership As Fair Value Stays In Focus

Amrize (SWX:AMRZ) appointed Mario Gross as President of its Building Envelope division following Jake Gosa's resignation. The company's shares trade at CHF32.07, down 15.3% over the past month and 28.5% over the last quarter. Analysts suggest a fair value of CHF46.66, citing potential earnings power and margin expansion from the ASPIRE synergy program. The P/E ratio is 17.3x, compared to an estimated fair ratio of 30.5x and a peer average of 48.6x.

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.